Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 25 of 124 for:    polycystic kidney disease

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

This study has been terminated.
(high rate of drop-out)
Information provided by (Responsible Party):
Zhi-Hong Liu, M.D., Nanjing University School of Medicine Identifier:
First received: November 25, 2008
Last updated: March 27, 2015
Last verified: March 2015
Triptolide has been approve effective in animal model.

Condition Intervention
Polycystic Kidney
Drug: tripterygium wilfordii
Drug: Emodin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Resource links provided by NLM:

Further study details as provided by Nanjing University School of Medicine:

Primary Outcome Measures:
  • MRI calculated kidney volume, eGFR [ Time Frame: Every 3-6months ]

Secondary Outcome Measures:
  • End-stage kidney disease (ESRD) [ Time Frame: every 2months ]

Enrollment: 300
Study Start Date: November 2008
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: emodin Drug: Emodin
Other Name: Frangula emodin,Frangulic acid
Experimental: Triptolide Woldifii
Drug: tripterygium wilfordii

Detailed Description:

Ages Eligible for Study:   15 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically established ADPKD
  • eGFR>30ml/min.
  • Chinese nationality

Exclusion Criteria:

  • Uncontrolled infections
  • Non-ADPKD complications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00801268

China, Jiangsu
Liu ZH, Yao XD,Chen X,Hu YL
Nanjing, Jiangsu, China, 210002
Yao Xiaodan
Nanjing, Jiangsu, China, 210002
Sponsors and Collaborators
Zhi-Hong Liu, M.D.
Principal Investigator: Liu Zhihong, Master Research Institute of Nephrology, Jinling Hospital
  More Information

Responsible Party: Zhi-Hong Liu, M.D., professor, Nanjing University School of Medicine Identifier: NCT00801268     History of Changes
Other Study ID Numbers: NJCT-0802
Study First Received: November 25, 2008
Last Updated: March 27, 2015

Keywords provided by Nanjing University School of Medicine:
polycystic kidney disease
tripterygium wilfordii

Additional relevant MeSH terms:
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Kidney Diseases, Cystic
Antispermatogenic Agents
Physiological Effects of Drugs
Contraceptive Agents, Male
Contraceptive Agents
Reproductive Control Agents
Immunosuppressive Agents
Immunologic Factors
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Gastrointestinal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on May 25, 2017